Top Rated Stock: Hidden Gems in Gaming, Metals & Health

Gaming explodes with record users, aluminum tightens on supply limits, and a pharma giant quietly reloads its obesity arsenal.

HERE ARE OUR PICKS FOR THIS WEEK!

----------------------------------------------------------

Roblox Corporation (RBLX): Immersive Platform Momentum Accelerating

Roblox delivered exceptional Q4 2025 results, with bookings reaching $2.22 billion—up 63% year-over-year and surpassing consensus estimates of $2.09 billion—highlighting robust monetization and viral content strength. Revenue climbed to $1.42 billion, a 43% increase, slightly below the $1.44 billion expectation, while net loss narrowed to $0.45 per share versus the anticipated $0.48 loss. User metrics shone brightly: daily active users (DAUs) surged to 144 million (up 69%, beating estimates of 140.39 million), and hours engaged totaled 35 billion (up 88%, exceeding 32.97 billion forecast).

CEO David Baszucki described 2025 as a banner year, exceeding annual guidance and long-term targets with record highs in DAUs, engagement, revenue, and bookings. Growth accelerated across regions, particularly APAC, supported by enhanced discovery tools and creator ecosystem improvements fostering higher-quality experiences.

For 2026, Roblox issued optimistic guidance: full-year bookings of $8.28 billion to $8.55 billion (above consensus $8.05 billion) and revenue of $6.02 billion to $6.29 billion (near $6.19 billion estimate), implying 22-26% bookings growth. Roth/MKM upgraded from Neutral to Buy, raising the target to $84 from $78, citing superior guidance, projected >20% bookings CAGR, and attractive valuation at 7x 2026 EV/bookings and 28x EV/EBITDA. The firm highlighted a "powerful, sustainable virtuous cycle" of better tools yielding superior content, elevating engagement and monetization.

Outlook:

Viral hits, advertising ramp-up, and platform scale position RBLX for 20-30%+ compounded growth, margin expansion from efficiency, and multi-bagger potential in the expanding metaverse/gaming market.

Alcoa Corporation (AA): Aluminum Strength Amid Supply Constraints

Alcoa Corporation reported strong Q4 2025 results, with adjusted EPS of $1.26 significantly beating consensus of $0.93, driven by higher aluminum prices offsetting tariff and cost pressures. Revenue reached $3.45 billion, exceeding estimates of $3.28 billion and up 15% sequentially, reflecting improved market fundamentals and operational execution.

Full-year production achieved records at multiple smelters and refineries, supported by $57 million in CO2 compensation from Spain and Norway.

CEO William F. Oplinger emphasized sustained progress in operations, strategy, and capital allocation despite challenges. For 2026, Alcoa anticipates higher aluminum output of 2.4-2.6 million metric tons (up from 2025 due to smelter restarts) and alumina production of 9.7-9.9 million metric tons. Shipments are projected at 2.6-2.8 million tons for aluminum and 11.8-12.0 million tons for alumina, with $750 million capex focused on low-cost enhancements.

Outlook:

Global aluminum dynamics favor tightness: China's primary capacity utilization nears policy limits at ~99%, while overseas additions remain constrained, sustaining shortages. Analysts forecast 2026 average aluminum prices up 15% year-over-year, bolstering margins amid demand from EVs, renewables, and infrastructure.

Pfizer Inc (PFE): Obesity Pipeline Rejuvenation Underway

Pfizer completed its $10 billion acquisition of Metsera in November 2025 (initial $7 billion enterprise value plus up to $20.65/share CVR), gaining a differentiated obesity portfolio including MET-097i (weekly/monthly GLP-1 RA entering Phase 3), MET-233i (monthly amylin analog), an oral GLP-1 candidate, and preclinical assets. This bolsters Pfizer's Internal Medicine pipeline, addressing prior setbacks like danuglipron discontinuation.

The deal positions Pfizer aggressively in the expanding obesity market, with Phase 3 trials for key candidates slated for 2026 and potential launches by 2028/2029. Management views the obesity opportunity as transformative, with peak sales potential in billions if milestones are achieved.

2026 guidance remains conservative, factoring in declining COVID product revenues and legacy patent expirations, while excluding offsets from new pipeline contributions. This embeds buffers for upside surprises, particularly if obesity assets advance faster or deliver strong data.

Outlook:

Recent momentum shows bottoming and rebound signs, with any positive obesity developments likely amplified by market enthusiasm. Broader strengths include diversified portfolio, scale advantages, and ongoing cost discipline.